Professor Jorn Dyerberg, PhD, MD, a pioneer in the discovery of omega-3s in foods and their powerful health benefits, will be the medical and scientific adviser for omega-3 fish oils at Cognis Nutrition & Health, Cognis announced today.
Dr. Dyerberg’s discoveries began in the 1970s, while studying the Greenland Inuit or Eskimo population. The Danish professor hypothesized that the rarity of coronary heart disease among the Inuit could be due to the omega-3 fatty acids found in their staple diet, based on cold-water oily fish. Together with his fellow countryman, Dr. Hans Olav Bang, he went on to demonstrate the unique physiological effects of these fatty acids. His work opened a whole new field of medical research and, since then, thousands of studies have been published and many are currently in progress.
Petra Mueller, Global Product Line Manager for Cognis Nutrition & Health’s omega-3s said: “It will be an honor for us to work with Professor Dyerberg. All Cognis products are based on sound science, which is at the heart of everything we do. So, who better to be our consultant than this pioneering scientist with unrivalled knowledge and expertise?”
The Omevitalä range of high purity omega-3 fatty acids is produced at the state-of-the-art facilities of Napro Pharma, now a fully-owned member of the Cognis Group. “We believe Omevitalä products to be the best on the market and now, appropriately, we have enlisted the best for the best!” Mueller said.
The consultancy arrangement with Cognis is inclusive of Napro Pharma and Marine Nutriceutical Corp, the group’s distribution partner in the USA for dietary supplements.
Cognis (www.cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a focus on the areas of wellness and sustainability. The company employs about 8,000 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural-source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, textiles, as well as agriculture and mining. The company holds a 50-percent stake in the joint venture Cognis Oleochemicals, one of the world’s leading manufacturers of oleochemicals.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2006, Cognis recorded sales of 3.37 billion euros and an Adjusted EBITDA (operating result) of 394 million euros.